Alamar Biosciences
Developer of ultra-sensitive, multiplex proteomic assays and automation for biomarker discovery and translational research. The company provides a sequential capture-and-release immunoassay platform, automated instrumentation with qPCR/NGS readouts, assay consumables, and data analysis software. It supports large-cohort plasma profiling and partnerships for therapeutic antibody access and biomarker-driven research.
Industries
Nr. of Employees
medium (51-250)
Alamar Biosciences
Patents
Products
Automated high-throughput instrument for multiplex proteomics
An all-in-one automated instrument that runs multiplexed immunoassays with reduced hands-on time and supports qPCR and NGS readouts for focused and highly multiplexed protein profiling.
Ultra-sensitive sequential-capture multiplex immunoassays and consumables
Assay kits and consumables implementing a sequential capture-and-release approach to increase signal-to-noise, enabling deep profiling of immune and neuro proteomes across many analytes.
Proteomic data analysis software
Software solutions for processing and interpreting multiplex assay readouts from instrument outputs into actionable proteomic datasets.
NULISAqpcr
Provides researchers with a flexible solution for creating targeted biomarker assays with high sensitivity and precision using their own antibodies.
NULISAqpcr Single-Plex Assays
Single-plex assays providing ultra-high sensitivity measurement of key biomarkers at low to sub fg/mL levels.
NULISAqpcr BD-pTau217 Assay
High sensitivity measurement of BD-pTau217 biomarker.
Automated high-throughput instrument for multiplex proteomics
An all-in-one automated instrument that runs multiplexed immunoassays with reduced hands-on time and supports qPCR and NGS readouts for focused and highly multiplexed protein profiling.
Ultra-sensitive sequential-capture multiplex immunoassays and consumables
Assay kits and consumables implementing a sequential capture-and-release approach to increase signal-to-noise, enabling deep profiling of immune and neuro proteomes across many analytes.
Proteomic data analysis software
Software solutions for processing and interpreting multiplex assay readouts from instrument outputs into actionable proteomic datasets.
NULISAqpcr
Provides researchers with a flexible solution for creating targeted biomarker assays with high sensitivity and precision using their own antibodies.
NULISAqpcr Single-Plex Assays
Single-plex assays providing ultra-high sensitivity measurement of key biomarkers at low to sub fg/mL levels.
NULISAqpcr BD-pTau217 Assay
High sensitivity measurement of BD-pTau217 biomarker.
Services
Collaborative access to an antibody discovery technology offered to pharmaceutical and biotechnology partners to support therapeutic antibody development.
Collaborative access to an antibody discovery technology offered to pharmaceutical and biotechnology partners to support therapeutic antibody development.
Expertise Areas
- Precision proteomics
- Biomarker discovery and validation
- Multiplex immunoassay development
- Automated assay workflow integration
Key Technologies
- Sequential capture-and-release immunoassay
- Ultra-sensitive detection (attomolar range)
- High-multiplex panels for proteomics
- Automated high-throughput instrumentation
News & Updates
Sponsorship and participation at the Biomarkers of Aging Conference, including poster presentations on proteomic modules enabled by the company's technology.
A hosted evening event for colleagues and collaborators during HAI Week focused on advances in Alzheimer’s imaging and neurodegenerative disease research.
Press release announcing $128M Series C financing and describing the company's platform capabilities, assay sensitivity, automation, and planned commercialization expansion.
Reference to a publication reporting plasma biomarker changes related to Alzheimer’s treatment, using the company's proteomic technology.
Achieved ISO 13485:2016 certification covering design and manufacture of medical and laboratory instruments and associated reagents (certificate available).
Completed SOC 2 report to validate security standards for protecting client data.
Sponsorship and participation at the Biomarkers of Aging Conference, including poster presentations on proteomic modules enabled by the company's technology.
A hosted evening event for colleagues and collaborators during HAI Week focused on advances in Alzheimer’s imaging and neurodegenerative disease research.
Press release announcing $128M Series C financing and describing the company's platform capabilities, assay sensitivity, automation, and planned commercialization expansion.
Reference to a publication reporting plasma biomarker changes related to Alzheimer’s treatment, using the company's proteomic technology.
Achieved ISO 13485:2016 certification covering design and manufacture of medical and laboratory instruments and associated reagents (certificate available).
Completed SOC 2 report to validate security standards for protecting client data.